HR and breast carcinoma: On the one hand, unlike other subtypes of breast cancer, HR+/HER2+ breast cancer is endowed with distinct molecular biological characteristics, therapeutic responses and drug resistance mechanisms due to the complex interaction between HR and the HER2 signaling pathway.5, 6